News

A landmark review on myeloproliferative neoplasms published in the New England Journal of Medicine

Researcher Isabelle Plo and Dr William Vainchenker, a haematologist and researcher at Gustave Roussy, have co-authored a landmark review on myeloproliferative neoplasms (MPNs), published in the New England Journal of Medicine on 19 August. The article summarises major advances in understanding these blood cancers and highlights therapeutic prospects that could transform their management in the years ahead.

Published on

Isabelle Plo - Dr William Vainchenker,

Blood cancers that can develop over decades

Myeloproliferative neoplasms (MPNs) encompass several bone marrow disorders. They are characterised by the excessive production of blood cells and can expose patients to serious complications, including thrombosis, bleeding or progression to acute leukaemia.

One of the major findings of recent years is that the mutations responsible for these diseases may arise several decades before diagnosis. MPNs therefore provide a unique model for understanding the earliest stages of cancer development and identifying opportunities for early intervention.

New therapeutic hopes

Although current treatments can effectively control the disease and reduce the risk of complications, in most cases they remain unable to achieve lasting elimination of the cells that cause it. However, the authors highlight the emergence of particularly promising new therapeutic strategies. Treatments specifically targeting mutated JAK2 or CALR proteins are currently being developed and could ultimately alter the course of the disease in a lasting way, or even eradicate the tumour clone responsible.

Deciphering the mechanisms behind cancer development

Beyond MPNs themselves, the review highlights the contribution these diseases make to cancer research as a whole. Because they develop slowly and their genetic alterations are now well characterised, they provide a model for studying how cancer arises and evolves over several decades.

This work paves the way for a better understanding of the mechanisms of tumour transformation and for the design of strategies capable of intercepting disease before cancer develops. This approach is fully aligned with Gustave Roussy's ambitions in precision medicine and cancer interception.

 infographic

International recognition of Gustave Roussy's expertise

This publication reflects the longstanding contribution of Gustave Roussy teams to understanding the biological mechanisms underlying these diseases, particularly mutations in the JAK2 gene, which have profoundly transformed diagnosis and patient management. 

Reference

Plo I., Vainchenker W. Myeloproliferative Neoplasms. New England Journal of Medicine, 20 August 2026: https://www.nejm.org/doi/pdf/10.1056/NEJMra2507867

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin